ADVM icon

Adverum Biotechnologies

3.26 USD
+0.03
0.93%
At close Apr 30, 4:00 PM EDT
1 day
0.93%
5 days
13.59%
1 month
-25.40%
3 months
-26.08%
6 months
-58.63%
Year to date
-32.08%
1 year
-66.46%
5 years
-97.25%
10 years
-98.98%
 

About: Adverum Biotechnologies Inc is a clinical-stage company that aims to establish gene therapy as a new standard of care for prevalent ocular diseases. It develops gene therapy product candidates intended to provide durable efficacy by inducing sustained expression of a therapeutic protein. Its product candidate, ixoberogene soroparvovec (Ixo-vec), is a single, in-office intravitreal (IVT) injection gene therapy product designed to deliver long-term durable therapeutic levels of aflibercept associated with a robust, sustained treatment response, reducing the treatment burden and fluctuations in macular fluid associated with bolus anti-vascular endothelial growth factor (VEGF) IVT injections.

Employees: 155

0
Funds holding %
of 7,425 funds
0
Analysts bullish %
of 3 analysts

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

125% more repeat investments, than reductions

Existing positions increased: 27 | Existing positions reduced: 12

100% more funds holding in top 10

Funds holding in top 10: 2 [Q3] → 4 (+2) [Q4]

5.13% less ownership

Funds ownership: 81.45% [Q3] → 76.32% (-5.13%) [Q4]

9% less funds holding

Funds holding: 76 [Q3] → 69 (-7) [Q4]

27% less call options, than puts

Call options by funds: $45K | Put options by funds: $62K

38% less capital invested

Capital invested by funds: $120M [Q3] → $74.1M (-$46M) [Q4]

44% less first-time investments, than exits

New positions opened: 9 | Existing positions closed: 16

Research analyst outlook

3 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target
$5
53%
upside
Avg. target
$23
595%
upside
High target
$33
912%
upside

3 analyst ratings

positive
67%
neutral
33%
negative
0%
Chardan Capital
Daniil Gataulin
22% 1-year accuracy
11 / 50 met price target
912%upside
$33
Buy
Maintained
17 Apr 2025
RBC Capital
Luca Issi
20% 1-year accuracy
11 / 54 met price target
53%upside
$5
Sector Perform
Maintained
16 Apr 2025
HC Wainwright & Co.
Matthew Caufield
25% 1-year accuracy
17 / 68 met price target
820%upside
$30
Buy
Reiterated
16 Apr 2025

Financial journalist opinion

Based on 35 articles about ADVM published over the past 30 days

Neutral
Accesswire
10 hours ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Adverum Biotechnologies, Inc. - ADVM
NEW YORK, NY / ACCESS Newswire / April 30, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Adverum Biotechnologies, Inc. ("Adverum" or the "Company") (NASDAQ:ADVM). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Adverum Biotechnologies, Inc. - ADVM
Neutral
Accesswire
12 hours ago
Adverum Biotechnologies, Inc. (ADVM) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation
NEW YORK, NY / ACCESS Newswire / April 30, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Adverum Biotechnologies, Inc. ("Adverum" or "the Company") (NASDAQ:ADVM). Investors who purchased Adverum securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/ADVM.
Adverum Biotechnologies, Inc. (ADVM) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation
Neutral
GlobeNewsWire
1 day ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Adverum Biotechnologies, Inc. - ADVM
NEW YORK, April 29, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of  Adverum Biotechnologies, Inc. (“Adverum” or the “Company”) (NASDAQ: ADVM).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Adverum Biotechnologies, Inc. - ADVM
Neutral
Accesswire
1 day ago
Bronstein, Gewirtz & Grossman, LLC Encourages Adverum Biotechnologies, Inc. (ADVM) Shareholders to Inquire about Securities Investigation
NEW YORK, NY / ACCESS Newswire / April 29, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Adverum Biotechnologies, Inc. ("Adverum" or "the Company") (NASDAQ:ADVM). Investors who purchased Adverum securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/ADVM.
Bronstein, Gewirtz & Grossman, LLC Encourages Adverum Biotechnologies, Inc. (ADVM) Shareholders to Inquire about Securities Investigation
Neutral
PRNewsWire
2 days ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Adverum Biotechnologies, Inc. - ADVM
NEW YORK , April 28, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Adverum Biotechnologies, Inc. ("Adverum" or the "Company") (NASDAQ: ADVM). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Adverum Biotechnologies, Inc. - ADVM
Neutral
Accesswire
2 days ago
Bronstein, Gewirtz & Grossman, LLC Is Investigating Adverum Biotechnologies, Inc. (ADVM) And Encourages Shareholders to Connect
NEW YORK, NY / ACCESS Newswire / April 28, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Adverum Biotechnologies, Inc. ("Adverum" or "the Company") (NASDAQ:ADVM). Investors who purchased Adverum securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/ADVM.
Bronstein, Gewirtz & Grossman, LLC Is Investigating Adverum Biotechnologies, Inc. (ADVM) And Encourages Shareholders to Connect
Neutral
GlobeNewsWire
5 days ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Adverum Biotechnologies, Inc. - ADVM
NEW YORK, April 25, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of  Adverum Biotechnologies, Inc. (“Adverum” or the “Company”) (NASDAQ: ADVM).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Adverum Biotechnologies, Inc. - ADVM
Neutral
Accesswire
5 days ago
Bronstein, Gewirtz & Grossman, LLC Encourages Adverum Biotechnologies, Inc. (ADVM) Stockholders to Inquire about Securities Investigation
NEW YORK, NY / ACCESS Newswire / April 25, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Adverum Biotechnologies, Inc. ("Adverum" or "the Company") (NASDAQ:ADVM). Investors who purchased Adverum securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/ADVM.
Bronstein, Gewirtz & Grossman, LLC Encourages Adverum Biotechnologies, Inc. (ADVM) Stockholders to Inquire about Securities Investigation
Neutral
Accesswire
5 days ago
Bronstein, Gewirtz & Grossman, LLC Encourages Adverum Biotechnologies, Inc. (ADVM) Stockholders to Inquire about Securities Investigation
NEW YORK, NY / ACCESS Newswire / April 25, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Adverum Biotechnologies, Inc. ("Adverum" or "the Company") (NASDAQ:ADVM). Investors who purchased Adverum securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/ADVM.
Bronstein, Gewirtz & Grossman, LLC Encourages Adverum Biotechnologies, Inc. (ADVM) Stockholders to Inquire about Securities Investigation
Neutral
Accesswire
6 days ago
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Adverum Biotechnologies, Inc. (ADVM) and Encourages Investors to Learn More About the Investigation
NEW YORK, NY / ACCESS Newswire / April 24, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Adverum Biotechnologies, Inc. ("Adverum" or "the Company") (NASDAQ:ADVM). Investors who purchased Adverum securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/ADVM.
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Adverum Biotechnologies, Inc. (ADVM) and Encourages Investors to Learn More About the Investigation
Charts implemented using Lightweight Charts™